This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

Exscientia announces multi-target, AI-driven drug discovery collaboration with Bristol Myers Squibb

19 May 2021

Upfront and potential milestones of over $1.2bn in addition to tiered royalties Exscientia, the clinical stage, Artificial Intelligence (AI)-driven pharmatech company, announced today that it has entered into a collaboration agreement with Bristol-Myers Squibb Company (NYSE: BMY).  This expanded collaboration has the potential to add to the Bristol Myers Squibb drug pipeline whilst enhancing Exscientia’s portfolio of shared assets. The... Read more

Magdalen College seeks Strategic Partner to accelerate development of The Oxford Science Park

Magdalen College seeks Strategic Partner to accelerate development of The Oxford Science Park

10 May 2021

Oxford, UK, May 10 2021 – Magdalen College Oxford, owner of The Oxford Science Park (TOSP), one of the UK’s leading parks for science and technology companies, has announced1 that it is seeking a strategic partner with which to accelerate development of the Park. At present, TOSP has approximately 250,000 sq ft of existing leased and managed buildings. Its 14.75 acres of development land has capacity to add a further 420,000 sq ft to support... Read more

Exscientia Receives Queen’s Award for Enterprise in Innovation

Exscientia Receives Queen’s Award for Enterprise in Innovation

29 Apr 2021

Exscientia, a clinical-stage Artificial Intelligence (AI)-driven pharmatech company, today announced that it has won the Queen’s Award for Enterprise in Innovation, recognising its pioneering work in the field of AI-driven drug discovery. Her Majesty the Queen has acknowledged the success of Exscientia’s AI-driven drug discovery platform, repeatedly taking new molecules from discovery to the clinic with unprecedented efficiency and with... Read more

Vaccitech Announces Pricing of Initial Public Offering

Vaccitech Announces Pricing of Initial Public Offering

29 Apr 2021

Oxford, UK – Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the pricing of its initial public offering in the United States of 6,500,000 American Depositary Shares (“ADSs”) representing 6,500,000 ordinary shares at an initial public... Read more

Exscientia announces investment of up to $525M

Exscientia announces investment of up to $525M

27 Apr 2021

Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia’s discretion Financing led by SoftBank Vision Fund 2 Exscientia, a clinical stage pharmatech company using artificial intelligence (AI) to design patient-based drugs, announced that it has completed a $225 million Series D funding round.... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More